-
1
Danger of co-administration ferric carboxymaltose and denosumab: hypophosphatemia
Published 2025-01-01Subjects: “…Denosumab…”
Get full text
Article -
2
Prevention and treatment of recurrent fractures after percutaneous vertebroplasty with denosumab in patients with osteoporotic vertebral compression fractures
Published 2025-01-01Subjects: “…denosumab…”
Get full text
Article -
3
The Influence of Vitamin D Levels and Supplementation on the Treatment of Patients Affected by MRONJ
Published 2025-01-01Subjects: Get full text
Article -
4
Do Unresectable Giant Cell Tumors of Bone Treated With Denosumab Progress After Discontinuation of Treatment?
Published 2025-01-01Subjects: “…denosumab…”
Get full text
Article -
5
-
6
Denosumab usage in atypical cemento-osseous dysplasia involving the entire mandible: a case report
Published 2025-01-01Subjects: Get full text
Article -
7
-
8
Medication related osteonecrosis (MRONJ) in the management of CTIBL in breast and prostate cancer patients. Joint report by SIPMO AND SIOMMMS
Published 2025-02-01Subjects: Get full text
Article -
9
The effect of denosumab vs. zoledronic acid in preventing skeletal-related events, including pain-related bone metastasis: a systematic review
Published 2024-10-01Subjects: Get full text
Article -
10
GIANT CELL TUMOR OF THE DISTAL RADIUS: FACTORS ASSOCIATED WITH LOCAL RECURRENCE
Published 2025-02-01Subjects: Get full text
Article -
11